Soluble prokaryotic expression of varicella-zoster virus glycoprotein E without N-terminal signal peptide and its immunogenicity evaluation

WEI Mingtong1, XIA Bingbing2, HE Zhiyuan2, ZHOU Wei2, LIU Xingdong3, ZHAO Jun2,4, CHEN Jingxian4, WANG Mingli2,4

Journal of Microbes and Infections ›› 2020, Vol. 15 ›› Issue (6) : 377-384.

PDF(8992 KB)
Welcome to visit Journal of Microbes and Infections,
PDF(8992 KB)
Journal of Microbes and Infections ›› 2020, Vol. 15 ›› Issue (6) : 377-384. DOI: 10.3969/j.issn.1673-6184.2020.06.006
Original Article

Soluble prokaryotic expression of varicella-zoster virus glycoprotein E without N-terminal signal peptide and its immunogenicity evaluation

  • WEI Mingtong1, XIA Bingbing2, HE Zhiyuan2, ZHOU Wei2, LIU Xingdong3, ZHAO Jun2,4, CHEN Jingxian4, WANG Mingli2,4
Author information +
History +

Abstract

Varicella zoster virus (VZV) glycoprotein E (gE) is the main candidate protein for VZV subunit vaccine. Unfortunately, the expression of gE in prokaryotic expression was mainly found in the inclusion body. In this study, a deletion of N-terminal 30 amino acids of gE was constructed on pET32a, expressed in BL21 (DE3). The soluble gE was purified and used to make polyclonal antibodies in BALB/c mice. The titer and specificity of polyclonal antibodies were determined by enzyme linked immunosorbent assay (ELISA) and indirect immunofluorescence. The results showed that the soluble recombinant gE produced by BL21/pET32a-VZV gE system is a practical way for vaccine development.

Key words

Varicella zoster virus / Glycoprotein E / Prokaryotic expression / Polyclonal antibody / Evaluation of immune

Cite this article

Download Citations
WEI Mingtong1, XIA Bingbing2, HE Zhiyuan2, ZHOU Wei2, LIU Xingdong3, ZHAO Jun2,4, CHEN Jingxian4, WANG Mingli2,4. Soluble prokaryotic expression of varicella-zoster virus glycoprotein E without N-terminal signal peptide and its immunogenicity evaluation[J]. Journal of Microbes and Infections. 2020, 15(6): 377-384 https://doi.org/10.3969/j.issn.1673-6184.2020.06.006

Funding

 
PDF(8992 KB)

Accesses

Citation

Detail

Sections
Recommended

/